Thermo Fisher Scientific Continues Investment in Global Manufacture of Bioprocessing Products
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Thermo Fisher Scientific Inc., has extended its manufacturing capability in Shanghai, China, for the production of Thermo Scientific Nunc Cell Factory single-use, certified-sterile bioprocessing systems.
This announcement forms part of a continuing strategy of global investment in the regional production of its high-quality bioprocessing products, to support the local bioproduction of vaccines, cell and protein therapeutics.
The Shanghai facility complements the Nunc™ Cell Factory production sites in Rochester, New York, and Roskilde, Denmark. Commenting on the new investment, Chuck Kummeth, president of the laboratory consumables division of Thermo Fisher Scientific said, “The Rochester, Roskilde and Shanghai sites are designed to meet local and international demands both now and in the future, and will facilitate the effective streamlining and continuity of supply for our growing customer base. Our aim is to provide regional biopharma production sites with the fastest and most efficient delivery of cell culture consumables, and to enable us to do this, we are currently investing heavily in the APAC region in particular.”
Thermo Scientifics bioprocessing products portfolio is complemented by media supplements, process liquids and cell culture sera, and the extended production facilities in Shanghai follows a recently opened site in Beijing dedicated to the hydration of cell culture media, and a joint venture in Lanzhou, China, for the collection, processing and selling of serum into local markets.
This announcement forms part of a continuing strategy of global investment in the regional production of its high-quality bioprocessing products, to support the local bioproduction of vaccines, cell and protein therapeutics.
The Shanghai facility complements the Nunc™ Cell Factory production sites in Rochester, New York, and Roskilde, Denmark. Commenting on the new investment, Chuck Kummeth, president of the laboratory consumables division of Thermo Fisher Scientific said, “The Rochester, Roskilde and Shanghai sites are designed to meet local and international demands both now and in the future, and will facilitate the effective streamlining and continuity of supply for our growing customer base. Our aim is to provide regional biopharma production sites with the fastest and most efficient delivery of cell culture consumables, and to enable us to do this, we are currently investing heavily in the APAC region in particular.”
Thermo Scientifics bioprocessing products portfolio is complemented by media supplements, process liquids and cell culture sera, and the extended production facilities in Shanghai follows a recently opened site in Beijing dedicated to the hydration of cell culture media, and a joint venture in Lanzhou, China, for the collection, processing and selling of serum into local markets.
